Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02811744 · ClinicalTrials.gov registry record · Phase 2
11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02811744: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT02811744 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02811744, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The proposed study aims to use 11C-acetate position emission tomography/computed tomography (PET/CT) to preliminarily test and validate methods for imaging astrocyte activation as an early indicator of neuroinflammation in Alzheimer's disease (AD). 11C-Acetate PET/CT has been shown to quantify astrocyte activation in vivo, but no reports have evaluated its potential in AD. The investigators propose to test 11C-Acetate PET/CT as a marker for astrocyte activation associated with pathologic amyloid deposition in AD. The investigators will compare binding between subjects with early stage AD and healthy controls. Further, the investigators will investigate the correlation between amyloid and acetate binding. If the investigators find increased astrocyte activation in response to cerebral amyloid by showing a group difference in brain acetate uptake between disease and controls or a strong correlation between acetate and amyloid PET/CT binding. Validating neuroinflammation markers in AD ultimately may guide therapeutic modulation of beneficial and damaging neuroinflammation to slow disease progression, as well as providing new insights into AD pathophysiology.
Interventions
- DRUG 11C-acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-01 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02811744
The ClinicalTrials.gov registry entry for NCT02811744 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 11C-acetate is the first listed.
NCT02811744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02811744 about?
NCT02811744 is a clinical study titled "11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation". The proposed study aims to use 11C-acetate position emission tomography/computed tomography (PET/CT) to preliminarily test and validate methods for imaging astrocyte activation as an early indicator of neuroinflammation in Alzheimer's disease (AD). 11C-Acetate PET/CT has been shown to quantify astro...
What is the current status of trial NCT02811744?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2017-01. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT02811744?
The interventions under investigation include: 11C-acetate (DRUG).
Who is sponsoring clinical trial NCT02811744?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.